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Abstract
In this study we report the effect of AZT on the whole protein expression profile both in the
control and the AZT-treated K562 cells, evidenced by two-dimensional gel electrophoresis and
peptide mass fingerprinting analysis. Two-dimensional gels computer digital image analysis showed
two spots that appeared up-regulated in AZT-treated cells and one spot present only in the drug
exposed samples. Upon extraction and analysis by peptide mass fingerprinting, the first two spots
were identified as PDI-A3 and stathmin, while the third one was proved to be NDPK-A.
Conversely, two protein spots were present only in the untreated K562 cells, and were identified
as SOD1 and HSP-60, respectively.
Background
AZT (3'-azido-3'-deoxythymidine or zidovudine), the first
anti-retroviral drug approved for AIDS therapy, is a syn-
thetic nucleoside analogue that inhibits HIV reverse tran-
scriptase activity in vitro [1]. It is often included as one of
the best anti-HIV 'drugs of choice' in highly active anti-ret-
roviral therapy (HAART) together with other non-nucleo-
side analogues and protease inhibitors [2-5]. Besides its
inhibitory effect on reverse transcriptase, AZT is known to
play a key role in many other cellular processes (e.g. pro-
tein and lipid glycosylation [6-8] , heme synthesis [9], free
radical generation [10-12] , apoptosis [13]).
Thus, in the last years, genes responding to AZT have been
identified in various cell lines [12-16]. These AZT-modu-
lated genes code mainly for proteins related either to cell
growth and/or homeostasis and metabolism. However,
recent reports have shown that AZT can also activate a
variety of signaling cascades (NF-kB-dependent) involved
in many other functions of crucial interest for the cell life
[17]. Moreover, AZT is also implicated in the oxidative
damage of DNA [18-20] , in the functional impairments
and structural destruction of mitochondria [12,21] and in
the induction of various transcription factors [14,22-24].
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The aim of this study was to extend our knowledge to AZT-
regulated cellular functions by identifying gene products
responsive to AZT. For this purpose we used K562 cells
untreated (control), or exposed to 20 µM AZT for 3 h. This
drug concentration is higher but not far from that found
in the blood of AIDS patients under AZT therapy. In addi-
tion, 20 µM AZT and 3 h exposure were selected also to
enhance the changes of new proteins under AZT influ-
ence, and to obtain the major differences without affect-
ing or damaging cells growth. After two-dimensional gel
electrophoresis, the protein expression profiles of these
two cell samples were previously inspected and then a dif-
ferential comparison based on peptide mass fingerprint-
ing analysis was performed. Our results showed that, with
respect to control cells, AZT-treated cells exhibited PDI-A3
and stathmin up-regulation (+400% and +140%, respec-
tively). On the other hand, SOD1 and HSP-60 were found
to be expressed only in control cells, while NADPK-A was
evidenced in the AZT-treated samples.
Results and discussion
To identify the proteins whose expression is responsive to
AZT, we performed two-dimensional gel electrophoresis
using protein extracts from K562 cells grown for 3 h in the
absence or in the presence of 20 µM AZT. Master maps of
control and AZT-treated K562 cells were generated by
analysis with the ImageJ software [25,26] after detection
of 624 spots by a medium-sensitivity stain such as micel-
lar Coomassie Brilliant Blue G250 [27,28]. Fingerprinting
by MALDI-ToF-MS analysis enabled the identification of
five different spots.
The major differences found when comparing both sets of
samples, the control untreated and the AZT-treated cells,
were the up-regulation of two proteins, the apparent
induction of a protein and the apparent silencing expres-
sion of two proteins by AZT. Following PMF the five pro-
teins were subsequently identified as protein disulfide
isomerase A3 (PDI-A3) and stathmin (up-regulated 4 and
1.4 fold, respectively; Fig. 1, right panel); nucleoside
diphosphate kinase A (NDPK-A; which was apparently
present only in the treated sample; Fig. 1, right panel);
cytosolic superoxide dismutase (SOD1) and 60 kDa heat
shock protein (HSP-60) (both apparently present only in
the control sample; Fig. 1, left panel; Table 1). The identi-
fied protein spots indicated in Fig. 1 by figure numbers
(1–5) were detected in duplicate in two different sample
preparations; the spots indicated in Fig. 1 by n.i. (not
identified) appeared only in the representative Coomassie
Blue stained 2DE gel (Fig. 1). To our knowledge, this
observation is the first one that shows the direct effect of
AZT on specific proteins expression.
Our results demonstrated that AZT regulated the expres-
sion of PDI-A3, an essential folding catalyst and chaper-
one of the ER [29-33]. This abundant protein introduces
disulfides into proteins (oxidase activity) and catalyzes
the rearrangement of incorrect disulfides (isomerase activ-
Representative Coomassie Blue G250-stained 2DE gel of K562 cells, developed in the IPG 3–10 linear interval Figure 1
Representative Coomassie Blue G250-stained 2DE gel of K562 cells, developed in the IPG 3–10 linear interval. Left side: con-
trol K562 cells; right side: AZT-treated K562 cells. 1: HSP-60; 2: PDI-A3; 3: NDPK-A; 4: Stathmin; 5: SOD1. n.i.: not identified.Proteome Science 2006, 4:4 http://www.proteomesci.com/content/4/1/4
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ity). Markovic et al. [34] recently confirmed a role for an
oxido-reductase activity, presumably that of PDI, in the
events that follow the HIV envelop binding to the mem-
brane of cell target receptors. In fact, it has been reported
that reduction of gp 120 disulfide bonds by PDI during
the viral interaction with the lymphocyte surface is a strict
requirement for the fusion [35,36]. However, it has been
reported that PDI-A3 may regulate signaling by sequester-
ing inactivated and activated Stat3 [37] and it is usually
up-regulated following an ER stress [38,39]. In this
respect, intriguingly, although AZT is known to inhibit
HIV reverse transcriptase activity, it could partly favor the
entry of HIV into the cell through PDI-A3. This hypothesis
should be indeed appropriately supported by specific
experiments which are beyond the aim of the present
study.
The other modulation by AZT of protein expression iden-
tified by 2DE was stathmin (oncoprotein 18; phospho-
protein p19) which was 1.4 fold up-regulated in AZT-
treated cells. This protein is a regulator of microtubule
(MT) dynamics that binds tubulin heterodimers and
destabilizes MTs by promoting catastrophes (i.e. transi-
tions from growing to shrinking MTs) [40]. Interestingly,
it has been found that microtubule protein contains also
an enzyme, namely NDP kinase responsible for the syn-
thesis of nucleoside triphosphates but also involved in
several regulatory processes associated with cells prolifer-
ation, development, and differentiation [41]. In particu-
lar, the so-called NDPK-A, encoded by the nm23-H1 gene,
is found only in the cytosol and is associated to tumour
progression and metastasis. By contrast, the so-called
NDPK-B, encoded by the nm23-H2 gene, is a transcrip-
tion factor for c-myc and it is found both in the cytosol
and in the nuclei [42]. Thus, in our experimental condi-
tions the 1.4-fold up-regulation of stathmin and the con-
comitant presence of NDPK-A in AZT-treated K562 cells
indicated a general effect of the drug on the microtubule
system. In this context, it is worth noting that agents able
to disrupt microtubules and some routes of intracellular
trafficking (e.g. nocodazole, colchicine), reduce the ability
of AZT to inhibit the cytotoxicity of ricin because of an
alteration in membrane translocation to the cytosol [43].
The last two proteins which appeared to be expressed only
in control cells, were identified as HSP-60 and SOD1,
respectively. HSP-60 is localized mainly in the mitochon-
dria [44] but it is also described to be associated with the
cell membrane [45,46]. The major role of HSP-60 is its
involvement in the folding of proteins during mitochon-
drial import; once properly folded the protein become
unable to be a target for binding to HSP-60 [47]. Interest-
ingly, it has been reported that HSP-60 interacts with
gp41, a transmembrane protein anchoring the surface
protein gp120 to the viral envelope of HIV; in addition
gp41 mediates the fusion between the viral and the host
cell membrane, a step which is essential for viral entry
[48]. Since the binding of HSP-60 to gp41 enhances the
infectivity of the virus by helping the virus both to anchor
it to the cell surface and to escape the attack of the
immune system [48], AZT could reduce the biological
activity of gp41 by silencing the HSP-60 expression, thus
preventing the entry of HIV into the cell. This attractive
hypothesis, which is linked to gp41 through HSP-60,
might counterbalance the effect of AZT on gp120 through
PDI-A3, as discussed before. Furthermore, it has also been
reported that HSP-60 stimulates the activity of HIV-1 ret-
roviral integrase, an enzyme which catalyzes a critical step
in the infectious cycle of this retrovirus, namely the inte-
gration of HIV-1 proviral DNA in the nuclear cell genome
[49].
Concerning SOD1, the other protein which seemed to be
silenced in the presence of AZT, it belongs to a family of
ubiquitous enzymes, found in all aerobic cells, which are
thought to provide primary defense against deleterious
effects of superoxide anions (O2 
-) by dismuting them to
hydrogen peroxide (H2O2) and molecular oxygen (O2)
[50]. There are two types of SOD in mammalian tissues: a
Cu2Zn2SOD in the cytosol (SOD1 or SOD-c) and a Mn-
SOD in the mitochondria [51]. The SOD1 was identified
as spot n. 5 in our 2DE (Fig. 1). Interestingly, it has been
previously found that AZT treatment of Tat mice causes
almost 80–90% suppression of Mn-SOD activity [52].
Therefore, a similar effect of AZT on SOD1 can not be
excluded in our experimental conditions. Since it has
been reported that the extracellular SOD (EC-SOD) activ-
ity of blood plasma decreases in HIV-infected patients
compared to healthy subjects, and also the SOD activity of
mononuclear cells decreases with the HIV-associated dis-
ease progression [53], our results are in line with these
observations and provide a further tool for a better knowl-
edge of the AZT-induced toxicity in AIDS patients treated
with this drug.
Conclusion
In conclusion, to date, this is the first report showing over-
expression of PDI-A3 and stathmin together with NDPK-
A appearance, in AZT-treated K562 cells, while HSP-60
and SOD1 were detected only in control untreated cells.
Of course, up/down regulation of these proteins could be
not just exclusive but probably part of a larger group of
proteins undetectable with our system. However, further
studies are in progress extending our observations to other
cell types in order to verify if the above reported altera-
tions are a general feature of the AZT- exposed cells or they
represent a peculiar behavior of a specific human chronic
myeloid (K562) leukemia cell line.Proteome Science 2006, 4:4 http://www.proteomesci.com/content/4/1/4
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Materials and methods
Chemicals and materials
All chemicals, but when specified were from Sigma-
Aldrich (St. Louis, MO, USA). The Multiphor system as
well as the linear Immobiline dry strips pH gradient 3–10
(11 cm long) were from Amersham (Milan, Italy).
Cells and growth conditions
Human chronic myeloid (K562) leukaemia cells were
obtained from the American Type Culture Collection
(ATCC), maintained in exponential growth in RPMI 1640
bicarbonate medium (pH 7.2) supplemented with 10%
(v/v) heat-inactivated foetal calf serum (FCS), 2 mM
glutamine and 0.1 mg/mL of both penicillin and strepto-
mycin and kept at 37°C in a humidified atmosphere of
5% CO2 in air. Cells, seeded at a density of 3 × 105 cells/
mL, were incubated in the absence or in the presence of 20
µM AZT for 3 h in routine experiments. Other experimen-
tal conditions were also tried (from 2 to 40 µM AZT from
5 min to 48 h), but the ones reported here were those that
gave both the best reproducibility of the data and the
major differences between untreated (control) and AZT-
treated cell samples. Therefore, a dose response or a time
response curve were not included since not necessary.
Cells in the exponential growth phase were harvested for
the experiments. However, cell growth did not show any
appreciable change at all the experimental conditions we
used. Cell counting and viability were determined at vari-
ous times by trypan blue exclusion method.
Cells treatment for proteomic analysis
K562 cells, incubated alone or with 20 µM AZT for 3 h at
37°C, were washed twice with PBS (20 mM K-phosphate
buffer, pH 7.2, containing 150 mM NaCl). The pelleted
cells (1 × 106 cells) were then treated with 10 µL of lysis
buffer (8 M urea, 2 % CHAPS, 0.3 % DTT, 2 % IPG buffer
pH 3–10 (Amersham, Milan, Italy), 5 µL bromophenol
blue) at 4°C for 20 min. Cell extracts were sonicated 4
times for 10 s each at the maximum power in an ice-bath
and then centrifuged for 15 min at 15,000 g (4°C). The
clear supernatants containing the proteins solutions were
collected and stored at -80°C for no more than a week
prior to the subsequent analyses. The protein concentra-
tion was determined according to Bradford [54].




Protein Gene name SWISS-PROT 
accession 
number
MW (expt/pred) pI (expt/pred) Trend in AZT-
treated cells
Observations and reported 
functions a
1 HSP-60 HSPD1 P10809 61187/62000 5.70/5.75 Absent Chaperone that accelerates 
the maturation of pro-
caspase by upstream 
activator proteases during 
apoptosis
2 PDI-A3 GRP58 P30101 57146/63000 5.98/5.80 Increased 4.0 -
fold
Chaperone in the 
endoplasmic reticulum lumen, 
may regulate signalling by 
sequestering inactive and 
activated Stat3




Found in reduced amount in 
tumor cells of high metastasic 
potential. May have distinct if 
not opposite roles in 
different tumors




STMN1 P16949 17161/19000 5.77/5.90 Increased 1.4-
fold
Microtubule-destabilizing 
proteins up-regulated in 
neoplastic cells; down-
regulation in malignant cells 
interferes with their 
progression through cell 
cycle and abrogates their 
transformed phenotype
5 Cu,Zn-SOD SOD1 P00441 16023/19000 5.70/5.75 Absent Cellular protective function 
against oxidative stress. 
Defects in SOD1 are the 
cause of familial amyotrophic 
lateral sclerosis (FALS) also 
called amyotrophic lateral 
sclerosis 1 (ALS1 or ALS).
a: from SWISS-PROT entryProteome Science 2006, 4:4 http://www.proteomesci.com/content/4/1/4
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Two-dimensional gel electrophoresis (2DE)
Approximately 800 µg of each sample protein extract were
treated with 2-D Clean-Up Kit (Amersham, Milan, Italy)
to eliminate high levels of salt and other interfering com-
pounds. The pellets (200 µg) were resuspended in 150 µl
rehydration solution (8 M urea, 0.5 % v/v Triton X-100,
20 mM DTT, 2 % v/v IPG buffer pH 3–10) for the first
dimension IEF. Eleven cm long, pH 3–10 immobilized
linear pH gradient strips were rehydrated with the sample
and then focused according to the method of Bjellqvist et
al. [55]. Briefly, IPG strips were equilibrated for 10 min
with IPG equilibration buffer (0.5 M Tris-HCl pH 6.8, 6 M
urea, 30% glycerol v/v, 1% SDS w/v, 0.6% DTT w/v). After
10 min the procedure was repeated with another IPG
equilibration buffer containing 0.3% w/v IAA instead of
DTT and 5 µl bromophenol blue solution. For the second
dimension, a vertical slab gel of 12.5% acrylamide was
used and SDS-PAGE was performed at 20 mA per gel for
60 min at a room temperature. Gels were stained over-
night with colloidal Coomassie blue (0.1% w/v Coomas-
sie Brilliant Blue G250, 34% v/v methanol, 3% v/v
phosphoric acid, and 17% w/v ammonium sulphate),
while destaining was performed with a solution of 5% v/
v acetic acid until a clear background was achieved [56].
Five replicas for each conditions (control and AZT-
treated) were made. In addition, the same experiments
were repeated twice and the spots which were constantly
reproduced, as well as those which showed a differential
intensity greater than 25%, were analyzed.
Protein pattern analysis
The 2DE gels were scanned by a standard PC work station
and analyzed with the ImageJ software [25,26] (Fig. 1). A
match set was created from the protein patterns of the two
independent cellular extracts (control K562 cells, AZT-
treated K562 cells). Spot amounts of the gels were normal-
ized to remove non-expression-related variations in spot
intensity. The results were evaluated in terms of spot pix-
els. Statistical analysis allowed the study of proteins that
were significantly increased (or decreased).
Protein identification by mass spectrometry
Selected spots were manually excised from gels and a large
number of samples were simultaneously digested with
trypsin using the In-gel Digest96 Kit™ (Millipore, Bedford,
MA, USA) according to the manufacturer's instructions. A
minimal aliquot of the obtained tryptic peptide mixture
was mixed with an equal volume of a solution of α-cyano-
4-hydroxy-trans-cinnamic acid matrix, saturated in 50% v/
v acetonitrile containing 0.1% v/v TFA, and spotted onto
a MALDI target plate. Matrix-assisted laser desorption/
ionization-time of flight-mass spectrometry (MALDI-ToF-
MS) analyses were performed in a Voyager-DE™ STR
instrument (Applied Biosystems, Framingham, MA, USA)
equipped with a 337 nm nitrogen laser and operating in
reflector mode. Mass data were obtained by accumulating
several spectra from laser shots with an accelerating volt-
age of 20,000 V. All mass spectra were externally cali-
brated using a standard peptide mixture containing des-
Arg-bradykinin (904.4681), angiotensin I (1296.6853),
1–17 (2093.0867) and 18–39 (2465.1989) adrenocorti-
cotropic hormone fragments. Two tryptic autolytic pep-
tides were also used for the internal calibration (m/z
842.5100 and 2807.3145) (Table 1). Validation of mass
spectrometric identifications was attempted by matching
in the Swiss-2DPage database http://www.expasy.ch.
Database searches
A monoisotopic mass list from each protein spot was
obtained from MALDI-ToF data after exclusion of
expected contaminant mass values (autolytic tryptic pep-
tides and tryptic human keratin fragments), automatically
achieved by the PeakErazor program http://www.pro
tein.sdu.dk/gpmaw/Help/PeakErazor/peakerazor.html.
These peptide mass fingerprints (PMF) were used to
search for human protein candidates in the SWISS-PROT
database using the Mascot search engine at the site http://
www.matrixscience.com, with the following parameters:
one missed cleavage permission, 50 ppm measurement
tolerance and at least five matching peptide masses. Oxi-
dation at methionine (variable modification) and S-car-
Table 2: Matching parameters associated to the identified proteins from K562 cells line. (C): control; (T): AZT-treated cells.
Spot Identification (Figure 1) Protein Sequence Coverage (%) Score Error (ppm)
1(C) HSP-60a 30 95 32
2(C) 2(T) PDI-A3a 19 18 88 86 19 9
3(T) NDPK-Ab 42 60 7
4(C) 4(T) Stathminc (oncoprotein 18; 
phosphoprotein p19)
35 18 62 44 20 7
5(C) Cu,Zn-SODa 50 67 19
a: matching with the liver master gel [57].
b: matching with the A549 cells 2D map [58].
c: matching with lymphocyte 2D map [59].Proteome Science 2006, 4:4 http://www.proteomesci.com/content/4/1/4
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boxyamidomethylation at cysteine residues (fixed
modification) were also considered. No post-translational
modifications were allowed. Positive identifications were
accepted with P values (the probability that the observed
match is a random event) higher than 0.05 (Table 2).
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